List of Tables
Table 1. Global Topoisomerase Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Topoisomerase Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Topoisomerase Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Topoisomerase Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Topoisomerase Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Topoisomerase Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Topoisomerase Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Topoisomerase Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Topoisomerase Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Topoisomerase Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Topoisomerase Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of Topoisomerase Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Topoisomerase Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Topoisomerase Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Topoisomerase Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Topoisomerase Inhibitors Sales by Region (K Units), 2021–2026
Table 18. Global Topoisomerase Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global Topoisomerase Inhibitors Sales by Region (K Units), 2027–2032
Table 20. Global Topoisomerase Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global Topoisomerase Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Topoisomerase Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global Topoisomerase Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Topoisomerase Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America Topoisomerase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Topoisomerase Inhibitors Sales by Country (K Units), 2021–2026
Table 27. North America Topoisomerase Inhibitors Sales by Country (K Units), 2027–2032
Table 28. North America Topoisomerase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Topoisomerase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Topoisomerase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Topoisomerase Inhibitors Sales by Country (K Units), 2021–2026
Table 32. Europe Topoisomerase Inhibitors Sales by Country (K Units), 2027–2032
Table 33. Europe Topoisomerase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Topoisomerase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Topoisomerase Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Topoisomerase Inhibitors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Topoisomerase Inhibitors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Topoisomerase Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Topoisomerase Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Topoisomerase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Topoisomerase Inhibitors Sales by Country (K Units), 2021–2026
Table 42. Latin America Topoisomerase Inhibitors Sales by Country (K Units), 2027–2032
Table 43. Latin America Topoisomerase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Topoisomerase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Topoisomerase Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Topoisomerase Inhibitors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Topoisomerase Inhibitors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Topoisomerase Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Topoisomerase Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Topoisomerase Inhibitors Sales (K Units) by Type (2021–2026)
Table 51. Global Topoisomerase Inhibitors Sales (K Units) by Type (2027–2032)
Table 52. Global Topoisomerase Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global Topoisomerase Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global Topoisomerase Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Topoisomerase Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Topoisomerase Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global Topoisomerase Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global Topoisomerase Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Topoisomerase Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Topoisomerase Inhibitors Sales (K Units) by Application (2021–2026)
Table 61. Global Topoisomerase Inhibitors Sales (K Units) by Application (2027–2032)
Table 62. Global Topoisomerase Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global Topoisomerase Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global Topoisomerase Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Topoisomerase Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Topoisomerase Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global Topoisomerase Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global Topoisomerase Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Topoisomerase Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Topoisomerase Inhibitors Product
Table 74. Roche Recent Developments/Updates
Table 75. Mundipharma Company Information
Table 76. Mundipharma Description and Business Overview
Table 77. Mundipharma Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Mundipharma Topoisomerase Inhibitors Product
Table 79. Mundipharma Recent Developments/Updates
Table 80. Purdue Pharma Company Information
Table 81. Purdue Pharma Description and Business Overview
Table 82. Purdue Pharma Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Purdue Pharma Topoisomerase Inhibitors Product
Table 84. Purdue Pharma Recent Developments/Updates
Table 85. Debiopharm Company Information
Table 86. Debiopharm Description and Business Overview
Table 87. Debiopharm Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Debiopharm Topoisomerase Inhibitors Product
Table 89. Debiopharm Recent Developments/Updates
Table 90. Ipsen Pharma Company Information
Table 91. Ipsen Pharma Description and Business Overview
Table 92. Ipsen Pharma Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Ipsen Pharma Topoisomerase Inhibitors Product
Table 94. Ipsen Pharma Recent Developments/Updates
Table 95. TopoGEN Company Information
Table 96. TopoGEN Description and Business Overview
Table 97. TopoGEN Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. TopoGEN Topoisomerase Inhibitors Product
Table 99. TopoGEN Recent Developments/Updates
Table 100. Novartis Company Information
Table 101. Novartis Description and Business Overview
Table 102. Novartis Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Novartis Topoisomerase Inhibitors Product
Table 104. Novartis Recent Developments/Updates
Table 105. Hikma Pharmaceuticals Company Information
Table 106. Hikma Pharmaceuticals Description and Business Overview
Table 107. Hikma Pharmaceuticals Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Hikma Pharmaceuticals Topoisomerase Inhibitors Product
Table 109. Hikma Pharmaceuticals Recent Developments/Updates
Table 110. Viatris Company Information
Table 111. Viatris Description and Business Overview
Table 112. Viatris Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Viatris Topoisomerase Inhibitors Product
Table 114. Viatris Recent Developments/Updates
Table 115. Pfizer Company Information
Table 116. Pfizer Description and Business Overview
Table 117. Pfizer Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Pfizer Topoisomerase Inhibitors Product
Table 119. Pfizer Recent Developments/Updates
Table 120. Merrimack Pharmaceuticals Company Information
Table 121. Merrimack Pharmaceuticals Description and Business Overview
Table 122. Merrimack Pharmaceuticals Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Merrimack Pharmaceuticals Topoisomerase Inhibitors Product
Table 124. Merrimack Pharmaceuticals Recent Developments/Updates
Table 125. Amgen Company Information
Table 126. Amgen Description and Business Overview
Table 127. Amgen Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Amgen Topoisomerase Inhibitors Product
Table 129. Amgen Recent Developments/Updates
Table 130. Johnson & Johnson Company Information
Table 131. Johnson & Johnson Description and Business Overview
Table 132. Johnson & Johnson Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Johnson & Johnson Topoisomerase Inhibitors Product
Table 134. Johnson & Johnson Recent Developments/Updates
Table 135. BioMérieux Company Information
Table 136. BioMérieux Description and Business Overview
Table 137. BioMérieux Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. BioMérieux Topoisomerase Inhibitors Product
Table 139. BioMérieux Recent Developments/Updates
Table 140. Promega Company Information
Table 141. Promega Description and Business Overview
Table 142. Promega Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Promega Topoisomerase Inhibitors Product
Table 144. Promega Recent Developments/Updates
Table 145. Takeda Pharmaceutical Company Information
Table 146. Takeda Pharmaceutical Description and Business Overview
Table 147. Takeda Pharmaceutical Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Takeda Pharmaceutical Topoisomerase Inhibitors Product
Table 149. Takeda Pharmaceutical Recent Developments/Updates
Table 150. Merck KGaA Company Information
Table 151. Merck KGaA Description and Business Overview
Table 152. Merck KGaA Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Merck KGaA Topoisomerase Inhibitors Product
Table 154. Merck KGaA Recent Developments/Updates
Table 155. Cipla Company Information
Table 156. Cipla Description and Business Overview
Table 157. Cipla Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Cipla Topoisomerase Inhibitors Product
Table 159. Cipla Recent Developments/Updates
Table 160. Teva Pharmaceuticals Indutries Company Information
Table 161. Teva Pharmaceuticals Indutries Description and Business Overview
Table 162. Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 163. Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Product
Table 164. Teva Pharmaceuticals Indutries Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Topoisomerase Inhibitors Distributors List
Table 168. Topoisomerase Inhibitors Customers List
Table 169. Topoisomerase Inhibitors Market Trends
Table 170. Topoisomerase Inhibitors Market Drivers
Table 171. Topoisomerase Inhibitors Market Challenges
Table 172. Topoisomerase Inhibitors Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
Table 176. Authors List of This Report
List of Figures
Figure 1. Product Picture of Topoisomerase Inhibitors
Figure 2. Global Topoisomerase Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Topoisomerase Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Etoposide Product Picture
Figure 5. Irinotecan Product Picture
Figure 6. Topotecan Product Picture
Figure 7. Other Product Picture
Figure 8. Global Topoisomerase Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Topoisomerase Inhibitors Market Share by Application: 2025 & 2032
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Home Care
Figure 13. Global Topoisomerase Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Topoisomerase Inhibitors Market Size (US$ Million), 2021–2032
Figure 15. Global Topoisomerase Inhibitors Sales (K Units), 2021–2032
Figure 16. Global Topoisomerase Inhibitors Average Price (US$/Unit), 2021–2032
Figure 17. Topoisomerase Inhibitors Report Years Considered
Figure 18. Topoisomerase Inhibitors Sales Share by Manufacturers in 2025
Figure 19. Global Topoisomerase Inhibitors Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Topoisomerase Inhibitors Players: Market Share by Revenue in Topoisomerase Inhibitors in 2025
Figure 21. Topoisomerase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Topoisomerase Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Topoisomerase Inhibitors Sales Market Share by Country (2021–2032)
Figure 24. North America Topoisomerase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 25. United States Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Topoisomerase Inhibitors Sales Market Share by Country (2021–2032)
Figure 28. Europe Topoisomerase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 29. Germany Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Topoisomerase Inhibitors Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Topoisomerase Inhibitors Revenue Market Share by Region (2021–2032)
Figure 36. China Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Topoisomerase Inhibitors Sales Market Share by Country (2021–2032)
Figure 44. Latin America Topoisomerase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Topoisomerase Inhibitors Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Topoisomerase Inhibitors Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Topoisomerase Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Topoisomerase Inhibitors by Type (2021–2032)
Figure 55. Global Revenue Market Share of Topoisomerase Inhibitors by Type (2021–2032)
Figure 56. Global Topoisomerase Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Topoisomerase Inhibitors by Application (2021–2032)
Figure 58. Global Revenue Market Share of Topoisomerase Inhibitors by Application (2021–2032)
Figure 59. Global Topoisomerase Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 60. Topoisomerase Inhibitors Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
